Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.

[powerpress]

Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for  patients with advanced NSCLC, as well as whether smoking status factors into her approach.

[powerpress]